NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Provided By PR Newswire

Last update: Aug 14, 2024

Successfully Completed a Financing of up to $70 Million, With $20 Million Upfront and an Additional $50 Million of Aggregate Gross Proceeds Upon the Exercise in Full of Clinical Milestone-Based Warrants